Acyclic Carbon To Carbon Unsaturation Patents (Class 514/710)
  • Patent number: 10098862
    Abstract: Pharmaceutical compositions of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone and pharmaceutically acceptable salts thereof are described as well as methods of their use.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 16, 2018
    Assignee: ONCONOVA THERAPEUTICS, INC.
    Inventor: Manoj Maniar
  • Patent number: 9060967
    Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: June 23, 2015
    Assignee: ONCONOVA THERAPEUTICS, INC
    Inventor: Manoj Maniar
  • Publication number: 20150132184
    Abstract: The invention relates to compositions including a charged oligo-phenylene ethynylene singlet-oxygen sensitizer and an oppositely-charged surfactant, which show an enhanced biocidal activity relative to a comparable concentration of the oligo-phenylene ethynylene without the oppositely-charged surfactant. The enhancement of biocidal activity is observed with an anionic oligo-phenylene ethynylene in the presence of a cationic surfactant such as TTAB, and with a cationic oligo-phenylene ethynylene in the presence of an anionic surfactant such as SDS.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 14, 2015
    Inventors: David G. Whitten, Eric H. Hill, Harry C. Pappas
  • Patent number: 8808702
    Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: August 19, 2014
    Assignee: Temple University-of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Patent number: 8759558
    Abstract: The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: June 24, 2014
    Assignee: Pronova Biopharma Norge AS
    Inventors: Anne Kristin Holmeide, Ragnar Hovland, Morten Brændvang
  • Patent number: 8637570
    Abstract: A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 28, 2014
    Assignee: Ferring International Center S.A.
    Inventors: Klaus Jensen, Soren Halskov, Henning Lund
  • Patent number: 8574609
    Abstract: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: November 5, 2013
    Inventor: John Alex Lopes
  • Patent number: 8476320
    Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of a compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: July 2, 2013
    Assignee: Onconova Therapeutics, Inc
    Inventors: Manoj Maniar, Janice W Bell
  • Patent number: 8431563
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 30, 2013
    Assignee: Amgen Inc.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, Jr., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang
  • Publication number: 20130012589
    Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.
    Type: Application
    Filed: March 24, 2011
    Publication date: January 10, 2013
    Applicant: ONCONOVA THERAPEUTICS, INC
    Inventor: Manoj Maniar
  • Publication number: 20130013334
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 10, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • Patent number: 8314145
    Abstract: The invention relates to a new process for the synthesis of high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17?-cyanomethyl-17?-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: November 20, 2012
    Assignee: Richter Gedeon Vegyeszeti Gyar RT
    Inventors: Lajosné Dancsi, Sándor Mahó, Antal Aranyi, János Horváth
  • Publication number: 20120225854
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 23, 2011
    Publication date: September 6, 2012
    Applicant: AMGEN INC.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, JR., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang
  • Patent number: 8247596
    Abstract: There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally substituted C3-C7 cycloalkyl or optionally substituted C5-C7 cycloalkenyl group, Q represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom, R1 and R3 independently represent optionally substituted C1-C4 chain hydrocarbon, halogen or hydrogen, R2 and R4 independently represent optionally substituted C1-C4 chain hydrocarbon, —C(?G)R5, cyano, halogen or hydrogen, G represents oxygen or sulfur, and R5 represents optionally substituted C1-C4 alkyl, hydroxyl, optionally substituted C1-C4 alkoxy, optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6 alkynyloxy, amino, optionally substituted C1-C4 alkylamino, optionally substituted di(C1-C4 alkyl)amino, C2-C5 cyclic amino or hydrogen.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: August 21, 2012
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Hiromasa Mitsudera
  • Patent number: 8106033
    Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: January 31, 2012
    Assignees: Temple University - Of The Commonwealth System of Higher Education, Mount Sinai School of Medicine
    Inventors: E. Premkumar Reddy, James F. Holland
  • Patent number: 8063109
    Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: November 22, 2011
    Assignee: Onconova Therapeutics, Inc.
    Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
  • Patent number: 7989502
    Abstract: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: August 2, 2011
    Assignees: SRI International, HealthPartners Research Foundation
    Inventors: Mary Ann Katherine Greco, William Howard Frey, II, Jacqueline DeRose, Rachel Beth Matthews, Leah Ranae Bresin Hanson
  • Publication number: 20110082176
    Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.
    Type: Application
    Filed: October 15, 2010
    Publication date: April 7, 2011
    Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
  • Publication number: 20110028504
    Abstract: A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective ?, ? unsaturated aryl sulfone, and at least one component selected from the group consisting of a) at least one water soluble polymer in an amount between about 0.5% and about 90% w/v, b) at least one chemically modified cyclodextrin in an amount between about 20% and about 60% w/v, and c) DMA in an amount between about 10% and about 50% w/v.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 3, 2011
    Applicant: ONCONOVA THERAPEUTICS, INC.
    Inventors: Manoj Maniar, Stanley C. Bell, Janice W. Bell
  • Patent number: 7763662
    Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: July 27, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Publication number: 20100087526
    Abstract: Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R1—X-A-B(R2)—Y or R1—X-A(R2)—B—Y, where R1 is preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the active site of PMPMEase and imparts hydrolysis resistance to the inhibitor, A and B are bridge atoms, and R2 is a characteristic-providing substituent.
    Type: Application
    Filed: April 6, 2009
    Publication date: April 8, 2010
    Inventor: Nararius Saah Lamango
  • Publication number: 20100028368
    Abstract: Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
    Type: Application
    Filed: December 12, 2007
    Publication date: February 4, 2010
    Applicant: TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: E. Premkumar Reddy, M.V. Ramana Reddy
  • Publication number: 20090306207
    Abstract: ?,?-Unsaturated sulfones, sulfoxides and sulfonamides according to Formula I: wherein Ar1, Ar2, X, n, * and R are as defined herein are useful for the treatment of proliferative disorders which are resistant to treatment by ATP-competitive kinase inhibitors.
    Type: Application
    Filed: January 4, 2006
    Publication date: December 10, 2009
    Inventors: M. V. Ramana Reddy, E. Premkumar Reddy, Stephen C. Cosenza, Stacey J. Baker
  • Publication number: 20090247624
    Abstract: Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective ?,? unsaturated aryl sulfone wherein the composition has a pH within the range of about 8 to about 9.
    Type: Application
    Filed: July 27, 2007
    Publication date: October 1, 2009
    Applicant: Onconova Therapeutics Inc.
    Inventors: Stanley C. Bell, Manoj Maniar
  • Patent number: 7595347
    Abstract: Pre-treatment with ?,? unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the ?,? unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: September 29, 2009
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
  • Publication number: 20090117207
    Abstract: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier, to an individual subject exposed to a poison. Optionally, an inventive method further includes administering a therapeutic agent to inhibit poison-caused pathology. A composition according to the invention is described which includes a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier.
    Type: Application
    Filed: November 29, 2005
    Publication date: May 7, 2009
    Inventors: Csaba K. Zoltani, Gennady E. Platoff, Steven I. Baskin
  • Publication number: 20090082371
    Abstract: A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-?B transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers may be accomplished utilizing quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, 7-Methoxy-5,11,12-trihydroxy-coumestan, and compounds similar to them alone or in combination with prior art other therapy.
    Type: Application
    Filed: June 19, 2006
    Publication date: March 26, 2009
    Inventor: Zhimin Lu
  • Publication number: 20080317815
    Abstract: One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising: H3C—(CH2)n—CHmCHmR, where is a single or double carbon-carbon bond, m is 1 or 2, n is 2 to 15, and R is a carboxylic acid, a salt, an ester, or an amide, where the ester or amide is an isostere or biostere of the carboxylic acid. The composition additionally contains an additive component selected from one or more of the group consisting of biocides, surfactants, antibiotics, antiseptics, detergents, chelating agents, virulence factor inhibitors, gels, polymers, pastes, edible products, and chewable products. The composition is formulated so that when it is contacted with a biofilm produced by a microorganism, where the biofilm comprises a matrix and microorganism on a surface, the dispersion inducer selectively acts on the microorganism and has a suitable biological response without a required direct effect on the matrix to disperse the biofilm.
    Type: Application
    Filed: May 14, 2008
    Publication date: December 25, 2008
    Applicant: Research Foundation of State University of New York
    Inventor: David G. Davies
  • Patent number: 7468393
    Abstract: Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: December 23, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Laura Catherine Cooper, Myra Gilligan, Alexander Charles Humphries, Peter Alan Hunt, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Monique Bodil Van Niel, Kevin Wilson
  • Publication number: 20080311183
    Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.
    Type: Application
    Filed: May 29, 2006
    Publication date: December 18, 2008
    Inventors: Brian R. Smith, Tak-Hang Chan, Brian Leyland-Jones
  • Patent number: 7407648
    Abstract: The use is described of merocyanine derivatives of formula (1), wherein R1 and R2 are each independently of the other hydrogen; C1-C22alkyl; cyclo-C3C8alkyl; or unsubstituted or C1-C5alkyl- or C1-C5alkoxy-substituted C6-C20aryl; orl; or R1 and R2 together with the nitrogen atom linking them form a —(CH2)m— ring which is uninterrupted or, interrupted by —O— or by —NH—; R3 is a cyano group; —COOR5; —CONHR5; —COR5; or —SO2R5; R4 is a cyano group; —COOR6; —CONHR6; —COR6; or —SO2R6; R5 and R6 are each independently of the other C1-C22alkyl; or unsubstituted or C1-C5alkyl substituted C6-C20aryl; or R3 and R4 together or R5 and R6 together form in a 5- to 7-membered, monocyclic, carbocyclic or heterocyclic ring; Z1, and Z2 are each independently of the other a —(CH2)n— group which is uninterrupted or interrupted by —O—, —S—, or by —NR7—, and/or is unsubstituted or substituted by C1-C5alkyl; R7 is (ClC5alkyl; 1 is from 1 to 4; m is from 1 to 7; n is from 1 to 4; when n=2, R1, R5 or R6 is a bivalent alkyl group; or R1
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: August 5, 2008
    Assignee: Ciba Specialty Chemicals Corp.
    Inventors: Barbara Wagner, Thomas Ehlis, Kai Eichin
  • Publication number: 20080145390
    Abstract: Method and article for providing a rapid, broad spectrum bacterial control, and a rapid and persistent antiviral control on an inanimate surface is disclosed. In the method, a compound or composition capable of lowering surface pH to less than about 4 is applied to the surface, and preferably is allowed to remain on the surface, and the nonvolatile components of the composition can form a barrier film or layer on a treated surface.
    Type: Application
    Filed: June 4, 2007
    Publication date: June 19, 2008
    Applicant: THE DIAL CORPORATION
    Inventors: Timothy J. Taylor, Harry E. Towner, Janice L. Fuls, Bruce R. Cox, George E. Fischler, Priscilla S. Fox, Nancy D. Rodgers, James Dalton, Daniel E. Pedersen, John J. Rolando, Richard K. Staub
  • Publication number: 20080058421
    Abstract: Biodegradable compositions for cleaning and disinfecting nasal tract and sinus cavity using food additive ingredients or ingredients that are safe.
    Type: Application
    Filed: June 19, 2007
    Publication date: March 6, 2008
    Inventor: John Alex Lopes
  • Patent number: 7217740
    Abstract: Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: May 15, 2007
    Assignee: Merck Sharp and Dohme
    Inventors: Jose Luis Castro Pineiro, Laura Catherine Cooper, Myra Gilligan, Alexander Charles Humphries, Peter Alan Hunt, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Monique Bodil Van Niel, Kevin Wilson
  • Patent number: 7056919
    Abstract: A wood treatment composition having a synergistic combination of fungicides which may include two or more compounds. These combinations are shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with these combinations. Also provided is wood treated by these combinations, and a method of treatment for composite wood.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: June 6, 2006
    Assignee: Kopcoat, Inc.
    Inventors: Alan S. Ross, Brian Marks, Hans Ward
  • Patent number: 7056953
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1, R2, R3, and R4 are as defined herein.
    Type: Grant
    Filed: May 18, 2004
    Date of Patent: June 6, 2006
    Assignee: Temple University - of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Patent number: 7053123
    Abstract: (E)-Styryl benzylsulfones useful as antiproliferative agents, including, for example, anticancer agents, are provided according to formula I: wherein: R1 is selected from the group consisting of halogen, C1–C6 alkoxy, nitro, phosphonato, amino, sulfamyl, carboxy, acetoxy and dimethylamino (C2–C6 alkoxy); and R2 and R3 are independently selected from the group consisting of halogen, C1–C6 alkoxy, C1–C6 alkyl, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, carboxy, acetoxy, and dimethylamino (C2–C6 alkoxy); provided: R1 may not be halogen when R2 and R3 are both halogen; R2 may not be 2-halogen when R3 is 4-halogen; or a pharmaceutically acceptable salt thereof; or formula II: wherein: R4 is selected from the group consisting of C1–C6 alkoxy, phosphonato, amino, sulfamyl, carboxy, acetoxy and dimethylamino (C2–C6 alkoxy); R6 is selected from the group consisting of nitro, hydrogen, phosphonato, amino, sulfamyl, carboxy, acetoxy and dimethylamino (C2–C6 alkoxy); and R7 is selected from the group consistin
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 30, 2006
    Assignee: Temple University-of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Patent number: 6833359
    Abstract: A method for reducing bacterial and fungal soil pathogens which comprises applying to a soil a chemically effective amount of a lignosulfonate, the amount preferably being between 0.05% and about 5% on a volume/weight basis. The method is effective in controlling a number of soil pathogens and can be used to treat the soil for diseases such as potato scab disease.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: December 21, 2004
    Assignee: Earth Alive Resources Inc.
    Inventor: George Lazarovits
  • Publication number: 20040229959
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: 1
    Type: Application
    Filed: May 18, 2004
    Publication date: November 18, 2004
    Applicant: Temple University - Of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M.V. Ramana Reddy
  • Publication number: 20040214903
    Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.
    Type: Application
    Filed: May 21, 2004
    Publication date: October 28, 2004
    Inventors: Stephen C. Cosenza, M.V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 6767926
    Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: July 27, 2004
    Assignee: Temple University - Of The Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 6762207
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, fluoro, chloro, iodo, bromo, C1-C6 alkyl, C1-C4 alkoxy, nitro, cyano and trifluoromethyl, with the proviso that (a) R1, R2, and R3 not all hydrogen when R4 is 2-chloro or 4-chloro; (b) when R1 and R3 are hydrogen and R2 is 4-bromo or 4-chloro, then R4 may not be 4-chloro, 4-fluoro or 4-bromo; (c) when R1 and R3 are hydrogen and R2 is 4-fluoro, then R4 may not be 4-fluoro or 4-bromo; (d) when R1 is hydrogen, and R4 is 2-fluoro, the R2 and R3 may not be 4-fluoro; and (e) when R1 is hydrogen and R3 is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R4 is 2-hydrogen, 2-chloro, or 2-fluoro; then R2 may not be 4-hydrogen, 4-chloro, 4-fluoro, or 4-bromo.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 13, 2004
    Assignee: Temple University - of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Patent number: 6756409
    Abstract: The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: June 29, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor De Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Jan-Bernd Lenfers
  • Patent number: 6749869
    Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: June 15, 2004
    Assignee: Ecolab
    Inventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
  • Patent number: 6699510
    Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: March 2, 2004
    Assignee: Ecolab Inc.
    Inventors: David D. McSherry, Francis L. Richter
  • Patent number: 6667346
    Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the toxic side effects of ionizing radiation. Administration of a radioprotective &agr;,&bgr; unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increase the dosage of anticancer radiation. In some instances, amelioration of toxicity following inadvertent radiation exposure may be mitigated with administration of &agr;,&bgr; unsaturated arylsulfone.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: December 23, 2003
    Assignees: Temple University - Of The Commonwealth System of Higher Education, Onconova Therapeutics, Inc.
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stephen C. Cosenza, Lawrence Helson
  • Patent number: 6656973
    Abstract: Provided are the compound (E)-4-carboxystyryl-4-chlorobenzyl sulfone, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: December 2, 2003
    Assignee: Temple University - Of the Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 6642271
    Abstract: This invention relates to novel compounds, capable of potentiating the efficacy of therapeutically active compounds, for example cytotoxic compounds used in the treatment of cancer. The novel compounds have been shown to increase the pharmacological activity of a conventional paclitaxel formulation and to make it possible to manufacture a new formulation of paclitaxel, exhibiting improved solubility, improved storage properties, and increased therapeutic efficacy as shown in the enclosed examples.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 4, 2003
    Assignee: Ardenia Investments, Ltd.
    Inventors: Oleg Strelchenok, Julian Aleksov
  • Publication number: 20030171441
    Abstract: The invention relates to the field of antiviral agents, and more specifically to antiviral therapy.
    Type: Application
    Filed: March 14, 2002
    Publication date: September 11, 2003
    Inventor: Johannes Servatius Leonardus Maria Nottet
  • Patent number: RE41279
    Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 27, 2010
    Assignee: Ecolab Inc.
    Inventors: David D. McSherry, Francis L. Richter